Dapagliflozin in diabetic keto acidosis

Reading File

Finding Sources

Searching PubMed

dapagliflozin AND "diabetic ketoacidosis"

Finding Sources

Reading File

Finding Sources

Reading File

I now have all the information needed for a thorough, well-sourced answer. Here is the complete response:

Dapagliflozin and Diabetic Ketoacidosis (DKA)

Dapagliflozin is an SGLT2 inhibitor that blocks the sodium-glucose cotransporter 2 in the proximal renal tubule, responsible for ~90% of filtered glucose reabsorption. This produces glucosuria, lowering the glycosuria threshold from ~180 mg/dL down to ~40 mg/dL. While its cardiorenal benefits are well established, its relationship with DKA is a key safety concern.

1. Mechanism of DKA with Dapagliflozin

The SGLT2 inhibitor-induced DKA risk arises through several interacting mechanisms:

Reduced insulin secretion: Glucosuria lowers blood glucose, which in turn suppresses endogenous insulin secretion.
Increased glucagon: Reduced glucose sensing at pancreatic alpha cells and direct SGLT2-independent effects increase glucagon, promoting hepatic ketogenesis.
Enhanced lipolysis: Elevated glucagon-to-insulin ratio shifts metabolism toward fat oxidation and ketone body production.
Low-insulin state: In insulin-deficient patients (T1DM, or T2DM patients with significant insulin deficiency), the reduced insulin level cannot suppress ketogenesis.

The net result is significant ketone body accumulation - often without marked hyperglycemia. - Goldman-Cecil Medicine, p. 2479; Fuster & Hurst's The Heart, 15th ed.

2. Euglycemic DKA - the Classic Pitfall

This is the most clinically dangerous scenario. Because dapagliflozin continuously excretes glucose in the urine:

Blood glucose remains relatively normal (e.g., 100-200 mg/dL), masking the severity of ketosis.
Patients - and clinicians - may not suspect DKA when glucose is near-normal.
Patients with T1DM who are taught to reduce insulin when glucose is normal may further withhold insulin, worsening ketoacidosis.

"Cases of euglycemic diabetic ketoacidosis have been reported with off-label use of SGLT2 inhibitors in patients with type 1 diabetes. Patients with type 1 diabetes are taught to give less insulin if their glucose levels are not elevated. Because patients with type 1 taking an SGLT2 inhibitor may have normal glucose levels, they may either withhold or reduce their insulin doses to such a degree as to induce ketoacidosis."

Katzung's Basic & Clinical Pharmacology, 16th ed., p. 1192

"Diabetic ketoacidosis (often with near-normal blood glucose) can occur in patients treated with SGLT2 inhibitors, especially during a concurrent illness."

Goodman & Gilman's Pharmacological Basis of Therapeutics

3. Risk Factors for DKA with Dapagliflozin

Risk Factor	Explanation
Type 1 diabetes	Absolute insulin deficiency, highest risk
Latent T1DM / insulin-deficient T2DM	Prone to ketosis even without labelled T1DM
Fasting / surgical state	Volume depletion + carbohydrate restriction drives ketosis
Concurrent illness	Increased counter-regulatory hormones
Caloric restriction / alcohol	Promotes starvation ketosis compounded by SGLT2 effects
Insulin dose reduction	Patients or providers reducing insulin because glucose "looks normal"
Perioperative period	Fluid shifts, fasting, stress hormones all converge

4. DKA Risk in T1DM: Approved Adjunct Use

Dapagliflozin (low dose) and sotagliflozin (SGLT1/2 dual inhibitor) are used as adjuncts to insulin in T1DM in many countries (though not approved for T1DM in the USA or UK):

They reduce HbA1c by 0.28-0.48%, promote weight loss, and reduce insulin dose requirements.
However, they precipitate DKA in 3-6% of T1DM individuals, which is the main reason for restricted/non-approval in some jurisdictions.
Goldman-Cecil Medicine, Adjunctive Therapies for T1DM

5. Perioperative Safety - Stop the Drug in Advance

All major anesthesia guidelines and the FDA recommend stopping SGLT2 inhibitors before elective surgery because of the combination of fasting, fluid shifts, and hormonal stress:

Dapagliflozin, canagliflozin, empagliflozin: Stop at least 3 days before elective surgery.
Ertugliflozin: Stop at least 4 days before.
Monitor blood glucose and ketones perioperatively even after stopping.

"Patients anticipating surgery should be instructed to discontinue these medications at least 3 (canagliflozin, dapagliflozin, or empagliflozin) or 4 days (ertugliflozin) before scheduled surgery to minimize the risk of postoperative diabetic ketoacidosis."

Morgan & Mikhail's Clinical Anesthesiology, 7th ed.

6. Clinical Diagnosis of Euglycemic DKA (SGLT2-related)

Because glucose is deceptively normal, the diagnosis requires:

Ketonemia / ketonuria - elevated beta-hydroxybutyrate
Elevated anion gap metabolic acidosis despite near-normal blood glucose
High index of suspicion in any patient on an SGLT2 inhibitor presenting with nausea, vomiting, abdominal pain, or malaise

7. Management

Management follows standard DKA principles, with specific considerations:

Stop dapagliflozin immediately.
IV fluids - correct volume depletion.
Insulin infusion - essential even though glucose may be near-normal; use dextrose-containing fluids (e.g., D5W or D10W) alongside insulin to prevent hypoglycemia while driving down ketones.
Electrolyte replacement - especially potassium.
Do not give more insulin without dextrose - the risk of hypoglycemia is high in euglycemic DKA.
Monitor anion gap and beta-hydroxybutyrate to track resolution, not just blood glucose.

8. Contraindications / When NOT to Use Dapagliflozin

Type 1 diabetes (off-label, high DKA risk; not approved in US/UK for this indication)
Patients very prone to ketosis - even if formally classified as T2DM
Pre-surgical/fasting state without dose interruption
Active DKA - absolute contraindication; do not continue during acute DKA

Recent Evidence

Recent systematic reviews and RCTs continue to investigate SGLT2 inhibitor safety and use in pediatric populations and T1DM:

[PMID 38776437] (RCT, Diabetes Care 2025) - SGLT2i + glucagon receptor antagonist combination in T1DM shows that the DKA risk with SGLT2i may be partially mitigated by glucagon suppression.
[PMID 40481206] (RCT, Nature Medicine 2025) - SGLT2 inhibitors as adjunct to insulin in youth with T1DM: confirms glycemic benefits but ongoing DKA risk monitoring is required.
[PMID 38635113] (Systematic Review, Paediatric Drugs 2024) - Dapagliflozin in pediatric indications: safety profile including DKA risk under review for this population.

Bottom line: Dapagliflozin causes DKA primarily by reducing insulin secretion and promoting glucagon-driven ketogenesis. The hallmark is euglycemic DKA - ketoacidosis without significant hyperglycemia - which is easily missed. Risk is highest in T1DM, perioperative settings, fasting, and illness. The drug should be stopped 3 days before surgery, and any patient on it presenting with acidosis/GI symptoms should have ketones and anion gap checked even if glucose is normal.

Dapagliflozin in diabetic keto acidosis

Reading File

Finding Sources

Searching PubMed

dapagliflozin AND "diabetic ketoacidosis"

Reading File

I now have rich, detailed content from multiple authoritative textbooks. Here is the comprehensive answer:

Dapagliflozin and Diabetic Ketoacidosis

Background: What is Dapagliflozin?

Dapagliflozin is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor. SGLT2 accounts for ~90% of renal glucose reabsorption in the proximal tubule (S1 segment). By blocking it, dapagliflozin lowers the glycosuria threshold from ~180 mg/dL down to ~40 mg/dL, causing continuous urinary glucose loss. The standard dose is 10 mg once daily (5 mg initial dose in hepatic failure). It lowers HbA1c by 0.5-1%, promotes 2-5 kg weight loss, and has proven cardio-renal benefits. - Katzung's Basic & Clinical Pharmacology, 16th ed.

The DKA Problem: Why It Happens

SGLT2 inhibitors are firmly linked to DKA through a cascade of metabolic shifts:

Reduced insulin secretion - Glucosuria lowers blood glucose; less glucose stimulus means less beta-cell insulin output.
Elevated glucagon - Lower glucose sensing at alpha cells increases glucagon secretion.
Promoted lipolysis - The high glucagon-to-insulin ratio shifts metabolism toward fat oxidation.
Ketogenesis - Free fatty acids flood the liver, driving ketone body production (beta-hydroxybutyrate, acetoacetate, acetone).

"SGLT2 inhibitors are also associated with increased risk of diabetic ketoacidosis, especially when used in patients with type 1 diabetes but also in type 2 diabetes, because the glucose-lowering effect leads to lower insulin secretion and a subsequent increased intrinsic ketogenesis related to the increased secretion of glucagon and the promotion of lipolysis."

Goldman-Cecil Medicine

Euglycemic DKA - The Most Dangerous Variant

This is the hallmark and most clinically treacherous complication. Because dapagliflozin continuously dumps glucose into the urine:

Blood glucose remains near-normal (often 100-250 mg/dL) despite significant ketoacidosis
The classic DKA marker of "high glucose" is absent - leading to delayed or missed diagnosis
Standard bedside glucose checks give false reassurance
Patients (and clinicians) who see normal glucose may reduce or withhold insulin, dramatically worsening ketosis

"Cases of euglycemic diabetic ketoacidosis have been reported with off-label use of SGLT2 inhibitors in patients with type 1 diabetes. Patients with type 1 diabetes are taught to give less insulin if their glucose levels are not elevated. Because patients with type 1 taking an SGLT2 inhibitor may have normal glucose levels, they may either withhold or reduce their insulin doses to such a degree as to induce ketoacidosis. Therefore, SGLT2 inhibitors should not be used in patients with type 1 diabetes and in those patients labelled as having type 2 diabetes but who are very insulin deficient and prone to ketosis."

Katzung's Basic & Clinical Pharmacology, 16th ed., p. 1192

"Patients with type 2 diabetes can develop ketoacidosis when on treatment with SGLT2 inhibitors. These patients often have euglycemia. SGLT2 inhibitors promote glucosuria, and euglycemic ketoacidosis can be precipitated by a fasting state common in the perioperative period."

Miller's Anesthesia, 10th ed.

Who is at Highest Risk?

Risk Category	Details
Type 1 diabetes	Absolute insulin deficiency - highest risk; SGLT2 inhibitors not approved for T1DM in USA/UK for this reason
Insulin-deficient T2DM	"Lean" T2DM patients prone to ketosis, or those misclassified as T2DM who are actually T1DM/LADA
Perioperative/fasting state	Reduced carbohydrate intake + fluid shifts + surgical stress hormones converge to drive ketosis
Concurrent illness	Infection, trauma, MI - any catabolic state with counter-regulatory hormone surge
Caloric restriction or alcohol	Starvation ketosis is potentiated by SGLT2-driven metabolic shift
Insulin dose reduction	Patients who lower insulin because glucose appears normal on SGLT2 inhibitor
Low-carbohydrate diet	Reduced glucose availability shifts substrate use toward ketones

Dapagliflozin as Adjunct in T1DM (Approved in Some Countries)

In type 1 diabetes, low-dose dapagliflozin and sotagliflozin (SGLT1/2 dual inhibitor) have been evaluated as insulin adjuncts:

Reduce HbA1c by 0.28-0.48%, promote weight loss, lower total insulin dose
However, they precipitate DKA in 3-6% of T1DM individuals - the primary barrier to approval
Approved as T1DM adjuncts in many parts of Europe and Australia, but NOT approved for T1DM in the USA or UK due to this unacceptable DKA risk

"These agents can precipitate diabetic ketoacidosis in 3 to 6% of individuals with type 1 diabetes and also increase the risk of developing urinary and genital yeast infections."

Goldman-Cecil Medicine

Perioperative Safety Protocol

The perioperative setting is extremely high risk for SGLT2 inhibitor-associated DKA due to the combination of fasting, fluid shifts, and stress hormones. All major guidelines mandate pre-surgical discontinuation:

Drug	Stop before elective surgery
Dapagliflozin	At least 3 days before
Canagliflozin	At least 3 days before
Empagliflozin	At least 3 days before
Ertugliflozin	At least 4 days before

"Canagliflozin, dapagliflozin, and empagliflozin should be stopped at least 3 days in advance of scheduled surgery, and ertugliflozin should be stopped at least 4 days before scheduled surgery. Adequate glucose control should be maintained by other means from the time these medications are discontinued until the postoperative period."

Morgan & Mikhail's Clinical Anesthesiology, 7th ed.

"With euglycemic DKA, dextrose may need to be added to fluids at the start of treatment."

Miller's Anesthesia, 10th ed.

Diagnosing Euglycemic DKA in a Patient on Dapagliflozin

Because glucose is normal, you must have a high index of suspicion and check:

Serum beta-hydroxybutyrate (elevated - more sensitive than urine ketones)
Arterial or venous blood gas - high anion gap metabolic acidosis (pH <7.3, bicarbonate <18 mEq/L)
Urine ketones (may be positive but less reliable than serum)
Serum electrolytes - calculate anion gap: Na - (Cl + HCO3) > 12 mEq/L

Any patient on an SGLT2 inhibitor with nausea, vomiting, abdominal pain, lethargy, or Kussmaul respirations must have ketones checked, even with a normal blood glucose.

Management of SGLT2 Inhibitor-Associated DKA

The approach follows standard DKA principles but with critical modifications:

Stop dapagliflozin immediately
IV fluids - correct volume depletion (normal saline initially)
Insulin infusion - essential even with near-normal glucose to suppress ketogenesis
Add dextrose (D5W or D10W) to IV fluids alongside insulin to prevent hypoglycemia while the insulin clears ketones - this is the key difference from hyperglycemic DKA management
Potassium replacement - insulin drives K+ intracellularly; replace aggressively
Monitor anion gap and beta-hydroxybutyrate to track resolution - not blood glucose alone
Treat the precipitant (infection, ischemia, medication non-compliance, etc.)

Key Takeaways

Point	Detail
Mechanism	Glucosuria → lower insulin, higher glucagon → lipolysis → ketogenesis
Hallmark	Euglycemic DKA - ketoacidosis with near-normal blood glucose
Biggest clinical trap	Normal glucose causes missed/delayed diagnosis
T1DM risk	3-6% DKA rate; not approved in USA/UK for T1DM
Perioperative rule	Stop dapagliflozin 3 days before elective surgery
Treatment modification	Use dextrose + insulin (not insulin alone) to avoid hypoglycemia during DKA resolution

Recent Evidence (PubMed, 2023-2025)

[PMID 38027214] - Systematic review/network meta-analysis (2023) comparing safety profiles of SGLT2 inhibitors at different doses in T2DM, including DKA rates
[PMID 38635113] - Systematic review of dapagliflozin and empagliflozin in pediatric indications (Paediatric Drugs 2024) - ongoing DKA risk monitoring in younger populations
[PMID 38776437] - RCT (Diabetes Care 2025) showing SGLT2i + glucagon receptor antagonist combination in T1DM may partially mitigate DKA risk by suppressing the glucagon-driven ketogenic stimulus
[PMID 40481206] - RCT (Nature Medicine 2025) of SGLT2 inhibitors as insulin adjuncts in youth with T1DM - confirms glycemic benefits but ongoing DKA risk management remains a priority

This is a shared conversation. Sign in to Orris to start your own chat.